Amylyx(AMLX) - 2025 Q1 - Quarterly Results

Exhibit 99.1 CAMBRIDGE, Mass. May 8, 2025 -- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today reported financial and business results for the first quarter ended March 31, 2025. "During the first quarter, we made continued progress across our pipeline, including strong clinical execution of our pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia. We remain focused on avexitide and continue to expect completion of enrollment in 2025 and topline data in the ...